Download PDF
Semin Liver Dis 2002; 22(4): 365-378
DOI: 10.1055/s-2002-35706
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Treatment of Autoimmune Hepatitis

Albert J. Czaja
  • Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota
Further Information

Publication History

Publication Date:
25 November 2002 (online)

    Permissions and Reprints

ABSTRACT

Corticosteroid therapy is effective in all forms of autoimmune hepatitis, and the combination of prednisone and azathioprine is preferred. Remission can be achieved in 80% of patients within 3 years, and the 10- and 20-year survival rates exceed 80%. Histological cirrhosis does not affect response or longevity, and all patients with severe disease should be treated, including children, elderly adults, postmenopausal women, individuals with acute or fulminant presentations, and those without conventional autoantibodies. Relapse is common, and long-term low-dose prednisone or azathioprine therapy is preferred after multiple relapses. Sustained remission is achievable, even after relapse, in 47% within 10 years, and the long-term maintenance regimens need not be indefinite. Liver transplantation is effective, and its actuarial 10-year survival rate is 75%. Drugs such as cyclosporine, tacrolimus, and mycophenolate mofetil promise greater blanket immunosuppression, and site-specific interventions are feasible, including blocking peptides, soluble cytotoxic T lymphocyte antigen-4, cytokine manipulations, T cell vaccination, oral tolerance, and gene therapy.

KEYWORDS

Corticosteroids - azathioprine - autoimmunity

REFERENCES

  • 1 Czaja A J. Drug therapy in the management of type 1 autoimmune hepatitis.  Drugs . 1999;  57 49-68
    PubMedSearch in Google Scholar
  • 2 Cook G C, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis.  QJM . 1971;  40 159-185
    PubMedSearch in Google Scholar
  • 3 Soloway R D, Summerskill W HJ, Baggenstoss A H. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis.  Gastroenterology . 1972;  63 820-833
    PubMedSearch in Google Scholar
  • 4 Murray-Lyon I M, Stern R B, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis.  Lancet . 1973;  1 735-737
    PubMedSearch in Google Scholar
  • 5 Summerskill W HJ, Korman M G, Ammon H V, Baggenstoss A H. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.  Gut . 1975;  16 876-883
    PubMedSearch in Google Scholar
  • 6 Roberts S K, Therneau T, Czaja A J. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis.  Gastroenterology . 1996;  110 848-857
    CrossrefPubMedSearch in Google Scholar
  • 7 Kanzler S, Lohr H, Gerken G, Galle P R, Lohse A W. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience.  Z Gastroenterol . 2001;  39 339-348
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 Davis G L, Czaja A J, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated HBsAg-negative chronic active hepatitis.  Gastroenterology . 1984;  87 1222-1227
    PubMedSearch in Google Scholar
  • 9 Czaja A J, Davis G L, Ludwig J, Taswell H F. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis.  Hepatology . 1984;  4 622-627
    PubMedSearch in Google Scholar
  • 10 Czaja A J, Ammon H V, Summerskill W HJ. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission.  Gastroenterology . 1980;  78 518-523
    PubMedSearch in Google Scholar
  • 11 Hegarty J E, Nouri-Aria K T, Portmann B, Eddleston A W F L, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis.  Hepatology . 1983;  3 685-689
    PubMedSearch in Google Scholar
  • 12 Czaja A J, Manns M P, McFarlane I G, Hoofnagle J H. Autoimmune hepatitis: the investigational and clinical challenges.  Hepatology . 2000;  31 1194-1200
    CrossrefPubMedSearch in Google Scholar
  • 13 Bratts R, Linden M. Cytokine modulation by glucocorticosteroids: mechanisms and actions in cellular studies.  Aliment Pharmacol Ther . 1996;  10 81-90
    PubMedSearch in Google Scholar
  • 14 Reichardt H M, Schutz G. Glucocorticoid signaling-multiple variations of a common theme.  Mol Cell Endocrinol . 1998;  146 1-6
    CrossrefPubMedSearch in Google Scholar
  • 15 De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors.  J Neuroimmunol . 2000;  109 16-22
    CrossrefPubMedSearch in Google Scholar
  • 16 Almawi W Y. Molecular mechanisms of glucocorticoid effects.  Modern Aspects of Immunobiology . 2001;  2 78-82
    PubMedSearch in Google Scholar
  • 17 Uribe M, Go V LW. Corticosteroid pharmacokinetics in liver disease.  Clin Pharmacokinetics . 1979;  4 233-240
    PubMedSearch in Google Scholar
  • 18 Uribe M, Go V LW, Kluge D. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects.  J Clin Gastroenterol . 1984;  6 331-335
    PubMedSearch in Google Scholar
  • 19 Schalm S W, Summerskill W HJ, Go V LW. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone.  Gastroenterology . 1977;  72 910-913
    PubMedSearch in Google Scholar
  • 20 Johnson P J. Immunosuppressive drug mechanisms. In: McFarlane IG, Williams R, eds. Molecular Basis of Autoimmune Hepatitis Austin, TX: RG Landes 1996: 177-191
    Search in Google Scholar
  • 21 Lennard L. Clinical implications of thiopurine methyltransferase-optimization of drug dosage and potential drug interactions.  Ther Drug Monit . 1998;  20 527-531
    CrossrefPubMedSearch in Google Scholar
  • 22 Schalm S W, Korman M G, Summerskill W HJ, Czaja A J, Baggenstoss A H. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns.  Am J Dig Dis . 1977;  22 973-980
    CrossrefPubMedSearch in Google Scholar
  • 23 DeGroote J, Fevery J, Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity.  Gut . 1978;  19 510-513
    PubMedSearch in Google Scholar
  • 24 Fevery J, Desmet V J, DeGroote J. Long-term follow-up and management of asymptomatic chronic active hepatitis. In: Cohen S, Soloway RD, eds. Chronic Active Liver Disease New York: Churchill Livingstone 1983: 51-64
    Search in Google Scholar
  • 25 Gregorio G V, Portmann B, Karani J. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study.  Hepatology . 2001;  33 544-553
    CrossrefPubMedSearch in Google Scholar
  • 26 Wang K K, Czaja A J. Prognosis of corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis in postmenopausal women: a retrospective analysis.  Gastroenterology . 1989;  97 1288-1293
    PubMedSearch in Google Scholar
  • 27 Schramm C, Kanzler S, Meyer zum Buschenfelde K-H, Galle P R, Lohse A W. Autoimmune hepatitis in the elderly.  Am J Gastroenterol . 2001;  96 1587-1591
    CrossrefPubMedSearch in Google Scholar
  • 28 Steven M M, Buckley J D, Mackay I R. Pregnancy in chronic active hepatitis.  QJM . 1979;  48 519-531
    PubMedSearch in Google Scholar
  • 29 Heneghan M A, Norris S M, O'Grady J G, Harrison P M, McFarlane I G. Management and outcome of pregnancy in autoimmune hepatitis.  Gut . 2001;  48 97-102
    CrossrefPubMedSearch in Google Scholar
  • 30 Varma R R, Michelsohn N H, Borkowf H I, Lewis J D. Pregnancy in cirrhotic and noncirrhotic portal hypertension.  Obstet Gynecol . 1977;  50 217-222
    PubMedSearch in Google Scholar
  • 31 Czaja A J, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis.  Gastroenterology . 1988;  95 448-453
    PubMedSearch in Google Scholar
  • 32 Nikias G A, Batts K P, Czaja A J. The nature and prognostic implications of autoimmune hepatitis with an acute presentation.  J Hepatol . 1994;  21 866-871
    CrossrefPubMedSearch in Google Scholar
  • 33 Davis G L, Czaja A J, Baggenstoss A H, Taswell H F. Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis.  Mayo Clin Proc . 1982;  57 303-309
    PubMedSearch in Google Scholar
  • 34 Alvarez F, Berg P A, Bianchi F B. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis.  J Hepatol . 1999;  31 929-938
    CrossrefPubMedSearch in Google Scholar
  • 35 Czaja A J, Carpenter H A, Santrach P J, Moore S B, Homburger H A. The nature and prognosis of severe cryptogenic chronic active hepatitis.  Gastroenterology . 1993;  104 1755-1761
    PubMedSearch in Google Scholar
  • 36 Ben Ari Z, Mehta A, Lennard L, Burroughs A K. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.  J Hepatol . 1995;  23 351-354
    CrossrefPubMedSearch in Google Scholar
  • 37 Heneghan M A, McFarlane I G. Current and novel immunosuppressive therapy for autoimmune hepatitis.  Hepatology . 2002;  35 7-13
    CrossrefPubMedSearch in Google Scholar
  • 38 Yates C R, Krynetski E Y, Loennechen T. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance.  Ann Intern Med . 1997;  126 608-614
    PubMedSearch in Google Scholar
  • 39 Rosenkrantz J G, Githens J H, Cox S M, Kellum D L. Azathioprine (Imuran) and pregnancy.  Am J Obstet Gynecol . 1967;  97 387-394
    PubMedSearch in Google Scholar
  • 40 Wang K K, Czaja A J, Beaver S J, Go V LW. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis.  Hepatology . 1989;  10 39-43
    PubMedSearch in Google Scholar
  • 41 Maggiore G, Bernard O, Hadchouel M. Treatment of autoimmune chronic active hepatitis in childhood.  J Pediatr . 1984;  104 839-844
    PubMedSearch in Google Scholar
  • 42 Roberts E A. Autoimmune hepatitis.  Indian J Pediatr . 1995;  62 525-531
    PubMedSearch in Google Scholar
  • 43 Czaja A J, Wolf A M, Baggenstoss A H. Laboratory assessment of severe chronic active liver disease (CALD): correlation of serum transaminase and gamma globulin levels with histologic features.  Gastroenterology . 1981;  80 687-692
    PubMedSearch in Google Scholar
  • 44 Schalm S W, Ammon H V, Summerskill W HJ. Failure of customary treatment in chronic active liver disease: causes and management.  Ann Clin Res . 1976;  8 221-227
    PubMedSearch in Google Scholar
  • 45 Czaja A J, Beaver S J, Shiels M T. Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis.  Gastroenterology . 1987;  92 215-219
    PubMedSearch in Google Scholar
  • 46 Czaja A J. Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis.  Hepatology . 1990;  11 1044-1049
    PubMedSearch in Google Scholar
  • 47 Stellon A J, Keating J J, Johnson P J, MacFarlane I G, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal.  Hepatology . 1988;  8 781-784
    PubMedSearch in Google Scholar
  • 48 Johnson P J, McFarlane I G, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis.  N Engl J Med . 1995;  333 958-963
    CrossrefPubMedSearch in Google Scholar
  • 49 Czaja A J, Menon K VN, Carpenter H A. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis.  Hepatology . 2002;  35 890-897
    CrossrefPubMedSearch in Google Scholar
  • 50 Seaberg E C, Belle S H, Beringer K C, Schivins J L, Detre K M. Liver transplantation in the United States from 1987-1998; updated results from the Pitt-UNOS liver transplant registry. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 1998 Los Angeles, CA: UCLA Tissue Typing Laboratories 1999: 17-37
    Search in Google Scholar
  • 51 Sanchez-Urdazpal L, Czaja A J, van Hoek B, Krom R AF, Wiesner R H. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis.  Hepatology . 1992;  15 215-221
    PubMedSearch in Google Scholar
  • 52 González-Koch A, Czaja A J, Carpenter H A. Recurrent autoimmune hepatitis after orthotopic liver transplantation.  Liver Transplantation . 2001;  4 302-310
    PubMedSearch in Google Scholar
  • 53 Hayashi M, Keefe E B, Krams S M. Allograft rejection after liver transplantation for autoimmune liver disease.  Liver Transpl Surg . 1998;  4 208-214
    CrossrefPubMedSearch in Google Scholar
  • 54 Kerkar N, Hadzic N, Davies E T. De-novo autoimmune hepatitis after liver transplantation.  Lancet . 1998;  353 409-413
    PubMedSearch in Google Scholar
  • 55 Heneghan M A, Portmann B C, Norris S M. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults.  Hepatology . 2001;  34 464-470
    CrossrefPubMedSearch in Google Scholar
  • 56 Salcedo M, Vaquero J, Banares R. Response to steroids in de novo autoimmune hepatitis after transplantation.  Hepatology . 2002;  35 349-356
    CrossrefPubMedSearch in Google Scholar
  • 57 Czaja A J. Autoimmune hepatitis after liver transplantation and other lessons of self intolerance.  Liver Transpl . 2002;  8 505-513
    CrossrefPubMedSearch in Google Scholar
  • 58 Dustin M L, Shaw A S. Costimulation: building an immunological synapse.  Science . 1999;  283 649-650
    CrossrefPubMedSearch in Google Scholar
  • 59 Calderhead D M, Kosaka Y, Manning E M, Noelle R J. CD40-CD154 interactions in B-cell signaling.  Curr Top Microbiol Immunol . 2000;  245 73-99
    PubMedSearch in Google Scholar
  • 60 McCoy K D, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses.  Immunol Cell Biol . 1999;  77 1-10
    CrossrefPubMedSearch in Google Scholar
  • 61 Alvarez F, Ciocca M, Canero-Velasco C. Short-term cyclosporine induces a remission of autoimmune hepatitis in children.  J Hepatol . 1999;  30 222-227
    CrossrefPubMedSearch in Google Scholar
  • 62 Malekzadeh R, Nasser-Moghaddam S, Kaviani M-J. Cyclosporin-A is a promising alternative to corticosteroids in autoimmune hepatitis.  Dig Dis Sci . 2001;  46 1321-1327
    CrossrefPubMedSearch in Google Scholar
  • 63 Van Thiel H D, Wright H, Carroll P. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial.  Am J Gastroenterol . 1995;  90 771-776
    PubMedSearch in Google Scholar
  • 64 Richardson P D, James P D, Ryder S D. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine.  J Hepatol . 2000;  33 371-375
    CrossrefPubMedSearch in Google Scholar
  • 65 Czaja A J, Lindor K D. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis.  Gastroenterology . 2000;  119 1312-1316
    PubMedSearch in Google Scholar
  • 66 Pratt D S, Flavin D P, Kaplan M M. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine.  Gastroenterology . 1996;  110 271-274
    PubMedSearch in Google Scholar
  • 67 Markham A, Bryson H M. Deflazacort. A review of its pharmacological properties and therapeutic efficacy.  Drugs . 1995;  50 317-333
    CrossrefPubMedSearch in Google Scholar
  • 68 Deflazacort-an alternative to prednisolone? Drug Ther Bull . 1999 37: 57-58
    Search in Google Scholar
  • 69 Rebollo Bernardez J, Cifuentes Mimoso C, Pinar Moreno A. Deflazacort for long-term maintenance of remission in type 1 autoimmune hepatitis.  Rev Esp Enferm Dig . 1999;  91 630-638
    PubMedSearch in Google Scholar
  • 70 Czaja A J, Carpenter H A, Lindor K D. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial.  Hepatology . 1999;  30 1381-1386
    CrossrefPubMedSearch in Google Scholar
  • 71 Nakamura K, Yoneda M, Yokohama S. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis.  J Gastroenterol Hepatol . 1998;  13 490-495
    PubMedSearch in Google Scholar
  • 72 Fridkis-Hareli M, Rosloniec E F, Fugger L, Strominger J L. Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses.  Hum Immunol . 2000;  61 640-650
    CrossrefPubMedSearch in Google Scholar
  • 73 Guinan E C, Boussiotis V A, Neuberg D. Transplantation of anergic histoincompatible bone marrow allografts.  N Engl J Med . 1999;  340 1704-1714
    CrossrefPubMedSearch in Google Scholar
  • 74 Wardrop R M, Whitacre C C. Oral tolerance in the treatment of inflammatory autoimmune diseases.  Inflamm Res . 1999;  48 106-119
    CrossrefPubMedSearch in Google Scholar
  • 75 Lohse A W, Dienes H P, Meyer zum Buschenfelde K-H. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression.  Hepatology . 1998;  27 1536-1543
    CrossrefPubMedSearch in Google Scholar
  • 76 Rutgeerts P, D'Haens G, Targan S. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.  Gastroenterology . 1999;  117 761-769
    CrossrefPubMedSearch in Google Scholar
  • 77 Nelson D R, Lauwers G Y, Lau J Y, Davis G L. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot study of interferon nonresponders.  Gastroenterology . 2000;  118 655-660
    CrossrefPubMedSearch in Google Scholar
  • 78 Touhy V K, Mathisen P M. Gene therapy for autoimmune diseases. In: Manns MP, Paumgartner G, Leuschner U, eds. Immunology and Liver Falk Symposium 114. Dordrecht, The Netherlands: Kluwer Academic 2000: 376-385
    Search in Google Scholar